Payment overview · 2025
General Payments
$181.62
9 reported records · 6 companies
Healthcare provider profile · identity verified
Michael Ramos, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAWTON, OK · NPI 1063407781
Verified facts
What the public records show
CMS Open Payments records show Michael Ramos, MD received $181.62 in general payments during 2025 across 9 reported records.
Lilly USA, LLC accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.78 | 24.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $42.83 | 23.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.86 | 21.9% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $20.93 | 11.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.60 | 10.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.62 | 8.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.62 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $42.83 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 221 | 35 |
| Omeprazole | Omeprazole | 198 | 42 |
| Alprazolam | Alprazolam | 188 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 42 |
| Gabapentin | Gabapentin | 169 | 31 |
| Simvastatin | Simvastatin | 160 | 37 |
| Metformin Hcl | Metformin Hcl | 149 | 32 |
| Lisinopril | Lisinopril | 138 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 126 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 122 | 18 |
| Furosemide | Furosemide | 114 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 22 |
| Ozempic | Semaglutide | 94 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 16 |
| Temazepam | Temazepam | 90 | 15 |
| Meloxicam | Meloxicam | 88 | 17 |
| Januvia | Sitagliptin Phosphate | 84 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 16 |
| Clonazepam | Clonazepam | 76 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 12 |
| Azithromycin | Azithromycin | 69 | 50 |
| Carvedilol | Carvedilol | 68 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 63 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 15 |
| Famotidine | Famotidine | 56 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 14 |
| Montelukast Sodium | Montelukast Sodium | 52 | 15 |
| Sertraline Hcl | Sertraline Hcl | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 52 | 11 |
| Losartan Potassium | Losartan Potassium | 51 | 16 |
| Trazodone Hcl | Trazodone Hcl | 49 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 12 |
| Eliquis | Apixaban | 43 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 43 | 14 |
| Potassium Chloride | Potassium Chloride | 43 | 12 |
| Estradiol | Estradiol | 42 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 12 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Oxycontin | Oxycodone Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 13 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.62 · 9 records | Lilly USA, LLC | AUSTEDO XR, MOUNJARO, NEFFY, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VOWST, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error